What is the 13F Pro Quality Score for PCSA?

13F Pro ranks Processa Pharmaceuticals, Inc. (PCSA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PCSA's current score at https://13fpro.ai/company/PCSA (free sign-up required for the full ranking).

Where does 13F Pro source PCSA data?

All Processa Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. Processa Pharmaceuticals, Inc. files with the SEC under CIK 1533743. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PCSA in?

Processa Pharmaceuticals, Inc. (PCSA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PCSA research updated on 13F Pro?

PCSA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Processa Pharmaceuticals, Inc.(PCSA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1533743 PCSA stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.5M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

PCSA Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for Processa Pharmaceuticals, Inc. (PCSA), a Healthcare sector company. PCSA is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.5m in revenue and is scored on the micro-cap board instead. Top institutional holders of PCSA by reported 13-F value include Connective Capital Management, Stonepine Capital Management, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. PCSA trades on the Nasdaq exchange and files with the SEC under CIK 1533743. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PCSA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Processa Pharmaceuticals, Inc. directly from SEC EDGAR.

✦

Fun facts about Processa Pharmaceuticals, Inc.

Quirks, history, and lore behind PCSA — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · micro-cap · listed on Nasdaq · headquartered in Maryland.
2
The Numbers
With minimal revenue and a market cap in the tens of millions, this is a company that lives on its pipeline, not its profits — the classic pre-commercial biotech math.
3
The History
Founded in the 2010s, it was built around a specific strategy: take existing drugs that have already cleared safety hurdles and re-develop them for unmet medical needs.
4
The Secret
Rather than discovering new molecules from scratch, the company focuses on repurposing or reformulating known compounds — a lower-risk path through the FDA pipeline.
5
The Lore
Its programs target conditions where patients have few or no approved options, making its niche as much about regulatory strategy as laboratory science.
6
The Giveaway
Ticker PCSA, based in Hanover, Maryland — a small pharma bet that old drugs still have new tricks left in them.

▶ Think you know your stocks? Play the Daily Ticker

Net Income

Q2 2026

$-3.3M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

—FY 2025

FY22 $0.00FY23 —FY24 —FY25 —

Net Income

-14.5% YoY

$-13.6MFY 2025

FY22 $-27.4MFY23 $-11.1MFY24 $-11.9MFY25 $-13.6M

Operating Income

-16.1% YoY

$-14.0MFY 2025

FY22 $-27.5MFY23 $-11.5MFY24 $-12.1MFY25 $-14.0M

EPS (Diluted)

+89.3% YoY

$-10.36FY 2025

FY22 $-34.05FY23 $-8.48FY24 $-96.78FY25 $-10.36

Total Assets

+142.0% YoY

$7.8MFY 2025

FY22 $8.6MFY23 $5.8MFY24 $3.2MFY25 $7.8M

Op. Cash Flow

-1.2% YoY

$-11.4MFY 2025

FY22 $-9.6MFY23 $-8.1MFY24 $-11.2MFY25 $-11.4M

Free Cash Flow

—FY 2025

FY22 —FY23 $-8.1MFY24 $-11.2MFY25 —

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	—	—	—	$0.00	$0.00	—
Net Income	$-13.6M -14.5%	$-11.9M -6.6%	$-11.1M +59.4%	$-27.4M -140.0%	$-11.4M +20.7%	$-14.4M
Operating Income	$-14.0M -16.1%	$-12.1M -5.2%	$-11.5M +58.4%	$-27.5M -126.9%	$-12.1M +19.8%	$-15.1M
EPS (Diluted)	$-10.36 +89.3%	$-96.78 -1041.3%	$-8.48 +75.1%	$-34.05	—	—
Total Assets	$7.8M +142.0%	$3.2M -44.2%	$5.8M -32.9%	$8.6M -67.4%	$26.5M +5.0%	$25.2M
Operating Cash Flow	$-11.4M -1.2%	$-11.2M -39.5%	$-8.1M +16.1%	$-9.6M -10.2%	$-8.7M -177.3%	$-3.1M
Free Cash Flow	—	$-11.2M -39.5%	$-8.1M	—	—	—

Get alerted when PCSA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Processa Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PCSA

Connective Capital Management, LLC
$163.7K85,274 sh
Stonepine Capital Management, LLC
$105.6K55,000 sh
GEODE CAPITAL MANAGEMENT, LLC
$42.4K22,090 sh
CITADEL ADVISORS LLC
$40.9K21,306 sh
StoneX Group Inc.
$29.6K11,437 sh
XTX Topco Ltd
$25.5K13,292 sh
JANE STREET GROUP, LLC
$25.5K13,264 sh
VANGUARD CAPITAL MANAGEMENT LLC
$24.4K12,729 sh
VANGUARD FIDUCIARY TRUST CO
$20.8K10,857 sh
UBS Group AG
$15.0K7,794 sh

Fund	Value	Shares
Connective Capital Management, LLC	$163.7K	85,274
Stonepine Capital Management, LLC	$105.6K	55,000
GEODE CAPITAL MANAGEMENT, LLC	$42.4K	22,090
CITADEL ADVISORS LLC	$40.9K	21,306
StoneX Group Inc.	$29.6K	11,437
XTX Topco Ltd	$25.5K	13,292
JANE STREET GROUP, LLC	$25.5K	13,264
VANGUARD CAPITAL MANAGEMENT LLC	$24.4K	12,729
VANGUARD FIDUCIARY TRUST CO	$20.8K	10,857
UBS Group AG	$15.0K	7,794

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PCSA on your watchlist

Track score changes the day Processa Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PCSA a good stock to buy?

13F Pro's AI-powered analysis of Processa Pharmaceuticals, Inc. (PCSA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PCSA are available on the PCSA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. PCSA is classified as a small company.

Which hedge funds own PCSA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PCSA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Processa Pharmaceuticals, Inc.'s investment landscape.